Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|March 9, 2018
Hearing Loss in Rheumatoid Arthritis
Which patients with RA are at greatest risk?
Advertisement
Reference1. Huang CM, Chen HJ, Huang PH, et al. Retrospective cohort study on risk of hearing loss in patients with rheumatoid arthritis using claims data. BMJ Open. 2018;8:e018134. doi: 10.1136/bmjopen-2017-018134.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement